Difference between revisions of "Meningioma"
Jump to navigation
Jump to search
m (→Regimen) |
Warner-admin (talk | contribs) m (Text replacement - "|Phase III (" to "|Phase 3 (") |
||
| Line 38: | Line 38: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669593/ Ji et al. 2015 (SWOG S9005)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669593/ Ji et al. 2015 (SWOG S9005)] | ||
|1992-1998 | |1992-1998 | ||
| − | |style="background-color:#1a9851"|Phase | + | |style="background-color:#1a9851"|Phase 3 (C) |
|[[#Mifepristone_99|Mifepristone]] | |[[#Mifepristone_99|Mifepristone]] | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of FFS | | style="background-color:#ffffbf" |Did not meet primary endpoint of FFS | ||
Revision as of 15:01, 12 February 2022
| Section editor | |
|---|---|
 |
Seema Nagpal, MD Stanford University Palo Alto, CA |
0 regimens on this page
0 variants on this page
|
Guidelines
EANO
NCCN
Unresectable, all lines of therapy
Placebo
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Ji et al. 2015 (SWOG S9005) | 1992-1998 | Phase 3 (C) | Mifepristone | Did not meet primary endpoint of FFS |
No active antineoplastic treatment.
References
- SWOG S9005: Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. link to original article link to PMC article PubMed NCT03015701